<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011663'>Arrhythmogenic right ventricular cardiomyopathy</z:hpo> (ARVC) is an inherited <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and a leading cause of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> in a young population </plain></SENT>
<SENT sid="1" pm="."><plain>ARVC is especially common in young athletes </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations in different desmosomal genes have been identified causing dysfunctional cell-cell contacts </plain></SENT>
<SENT sid="3" pm="."><plain>Reduced myocardial expression of plakoglobin in the cell-cell contact complexes appears to associate with disease manifestation in patients harbouring mutations within other cell-cell contact genes </plain></SENT>
<SENT sid="4" pm="."><plain>Experimental data suggest that preload reduction may be a simple and effective intervention to prevent disease progression and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in ARVC </plain></SENT>
<SENT sid="5" pm="."><plain>This review discusses the potential effects of this innovative approach and describes the design of the first controlled trial of preload-reducing therapy in patients with ARVC </plain></SENT>
</text></document>